09:20 AM EST, 02/17/2026 (MT Newswires) -- Moleculin Biotech ( MBRX ) said Tuesday that Japan's Patent Office has issued a notice of allowance for a patent covering Annamycin.

A patent from the application is slated to be issued in the coming months, the company said.

Moleculin's drug candidate Annamycin is in development to treat acute myeloid leukemia and other blood diseases, the company said.

Moleculin shares were up past 5% in recent premarket activity.